Vivani’s lead program, NPM-115, utilizes a miniature, six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in obese or overweight individuals.
State Street Corp increased its position in InMode Ltd. (NASDAQ:INMD – Free Report) by 3.7% during the third quarter, HoldingsChannel reports. The institutional investor owned 2,044,640 shares of the ...
The device combines the subdermal sensors with wireless communication using near-field communication (NFC) signals that can deliver real-time readings of three hormones to a smartphone.